Navigation Links
Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
Date:8/18/2009

Zurich, Switzerland, August 18, 2009 / b3c newswire / -Neurimmune Therapeutics AG today announced that, following the successful completion of key research milestones, its lead human therapeutic antibody for Alzheimers disease has advanced into preclinical development, triggering milestone payments of an undisclosed amount from Biogen Idec (NASDAQ: BIIB). Neurimmune partnered with Biogen Idec for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimers disease in November 2007. The alliance focuses on the development of antibodies that bind to amyloid beta (Abeta), a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in Alzheimers patients.

Neurimmunes unique Reverse Translational Medicine (RTM) technology platform combined with in-depth expertise in neuroscience played a critical role in moving the program forward. The fact that we could reach all preclinical milestones in such a short period of time shows that our RTM technology can significantly accelerate the transition from discovery to development of human monoclonal antibodies, said Jan Grimm, Chief Scientific Officer of Neurimmune Therapeutics.

The rapid advancement into preclinical development demonstrates the progress and productivity of our collaboration with Biogen Idec we are very happy to work with a partner that has such extensive and valuable experience in the development of biopharmaceuticals. The significant milestone payments also provide Neurimmune with additional financial stability to support the sustainable future development of our company, said Michael Salzmann, COO and General Manager of Neurimmune Therapeutics.

Biogen Idec is globally recognized as a leader in the development of innovative therapies for neurologic diseases, and this program is an important entry into Alzheimers disease for us, said Kenneth Rhodes, PhD, Vice President, Discovery
'/>"/>
b3c newswire

Page: 1 2 3

Related biology news :

1. Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
2. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
3. NIH announces new program to develop therapeutics for rare and neglected diseases
4. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
5. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
6. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
7. A novel target for therapeutics against Staph infection
8. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
9. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
10. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
11. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... experiments with mice, a team of scientists from the United ... dose of one protein is sufficient to change the normal ... doubling the risk that a cancer-causing genetic mutation will trigger ... double protein dose as well. , In the Feb. 24 ...
... broadens our insight into,the cause of certain kinds ... Center (Rotterdam, The Netherlands) have,employed an evolutionarily ancient ... damage responsible for the onset of skin-tumor,development. The ... be useful in developing preventative therapies against skin,cancer. ...
... study published in the journal Blood, Yale scientists identify the ... to clonally expand into large populations of malignant lymphocytes. , ... the white blood cells of the immune system. Finding CTCL ... Edelson, M.D., Director of the Yale Cancer Center, and professor ...
Cached Biology News:It's not all genetic: Common epigenetic problem doubles cancer risk in mice 2It's not all genetic: Common epigenetic problem doubles cancer risk in mice 3Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer 2Source of molecular triggers in cutaneous T cell lymphoma identified 2
(Date:5/20/2015)... , May 20, 2015  Marc Tessier-Lavigne, ... leadership gift of $100 million from The Marie-Josée ... a new laboratory building that will be the ... The Marie-Josée and Henry R. Kravis Research Building, ... FDR Drive, spanning approximately three city blocks following ...
(Date:5/20/2015)... , May 20, 2015  Cypher Genomics, ... a collaboration with Celgene Corporation to apply Cypher,s ... biomarkers that associate with patient response to innovative ... intended to help accelerate patient access to the ... in clinical research and development and potentially inform ...
(Date:5/20/2015)... 19, 2015 Research and Markets ... the "Bone Morphogenetic Proteins Market (Types : ... and Oral - Maxillofacial) - Global Industry Analysis, ... 2022" report to their offering. ... based on the types of recombinant BMPs, applications, ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 ... transporter assay services for Drug-Drug Interactions (DDI), Metabolism ... Pharma, a world leader in assessing impact of ... Systems Pharmacology supported by biosimulation, announced today that ... agreement allows both companies to expand their product ...
Breaking Biology Technology:The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... CHICAGO, Sept. 3 The Female Health Company (Nasdaq: ... Female Condom® , today announced that the Company,s CEO, O.B. ... a presentation at Rodman & Renshaw,s Global Investment Conference ... the Hubbard Salon, 5th floor. The Conference will ...
... -- DALLAS, Texas, September 3, 2010 ... ... ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Researchers at the Georgia Institute of Technology have developed ... current is switched by an electric field generated by ... The devices, which include transistors and diodes, could ... systems (MEMS) and microfluidic devices. The mechanical action ...
Cached Biology Technology:The Female Health Company to Present at Rodman & Renshaw's Annual Global Investment Conference on Wednesday, September 15, 2010 2New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 2New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 3New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 4New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 5New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 6New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 7New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 8Researchers create new class of piezoelectric logic devices using zinc oxide nanowires 2Researchers create new class of piezoelectric logic devices using zinc oxide nanowires 3Researchers create new class of piezoelectric logic devices using zinc oxide nanowires 4
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Request Info...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
albumin from bovine serum (BSA), Texas Red® conjugate...
Biology Products: